Neuronetics (NASDAQ:STIM) Major Shareholder Buys $238,955.52 in Stock

Neuronetics, Inc. (NASDAQ:STIM) major shareholder Jorey Chernett bought 169,472 shares of the stock in a transaction on Friday, March 20th. The shares were acquired at an average cost of $1.41 per share, for a total transaction of $238,955.52. Following the completion of the transaction, the insider directly owned 8,743,276 shares of the company’s stock, valued at approximately $12,328,019.16. The trade was a 1.98% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Jorey Chernett also recently made the following trade(s):

• On Thursday, March 19th, Jorey Chernett purchased 450,000 shares of Neuronetics stock. The stock was bought at an average cost of $1.33 per share, with a total value of $598,500.00.
• On Wednesday, March 18th, Jorey Chernett acquired 607,400 shares of Neuronetics stock. The shares were bought at an average cost of $1.35 per share, for a total transaction of $819,990.00.
• On Tuesday, March 17th, Jorey Chernett acquired 531,000 shares of Neuronetics stock. The stock was bought at an average cost of $1.16 per share, for a total transaction of $615,960.00.

Neuronetics Stock Down 3.8%

STIM opened at $1.40 on Thursday. The firm has a market cap of $96.99 million, a P/E ratio of -2.37 and a beta of 0.87. The company has a debt-to-equity ratio of 2.51, a quick ratio of 1.87 and a current ratio of 2.02. The business has a 50 day moving average price of $1.57 and a 200 day moving average price of $1.98. Neuronetics, Inc. has a twelve month low of $0.80 and a twelve month high of $4.85.

Neuronetics (NASDAQ:STIM) last announced its quarterly earnings results on Tuesday, March 17th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.02. Neuronetics had a negative return on equity of 121.26% and a negative net margin of 26.15%.The company had revenue of $41.78 million for the quarter, compared to the consensus estimate of $40.84 million. Research analysts forecast that Neuronetics, Inc. will post -1.13 EPS for the current year.

Neuronetics News Summary

Here are the key news stories impacting Neuronetics this week:

• Positive Sentiment: Major shareholder Jorey Chernett has been buying aggressively (most recently 169,472 shares at ~$1.41; multiple prior purchases totaling >1.5M shares over several days), signaling insider confidence and adding a strong demand signal. Major Shareholder Jorey Chernett Buys 169,472 Shares
• Positive Sentiment: Company reported higher revenue and a narrower loss and provided a 2026 outlook, which supports fundamentals after the March 17 quarter. That underlying operational improvement is a bullish datapoint for longer-term recovery. Neuronetics reports higher revenue, narrows loss, sets 2026 outlook
• Neutral Sentiment: Board/leadership change — Dan Reuvers has been appointed CEO, succeeding Keith Sullivan; leadership transitions can be neutral-to-positive depending on execution and investor confidence. Neuronetics appoints Dan Reuvers as CEO
• Neutral Sentiment: Reported short-interest entries for late March show anomalous/zero values across several feeds (likely data/reporting artifacts), so short-interest signals are currently unreliable as a trading driver. (No actionable change tied to clean short-interest data.)
• Negative Sentiment: Several insiders (EVPs William Macan and Steven Pfanstiel; Director Keith Sullivan) sold shares (~78k combined) at roughly $1.34 per share, modestly reducing insider ownership and potentially adding selling pressure. SEC filing (insider sales)
• Negative Sentiment: Analyst actions are mixed-to-negative: Canaccord cut its price target (from $7 to $3) despite a buy rating; other shops have downgraded or maintained sell views, which can pressure sentiment and limit near-term upside. (MarketBeat/analyst notes)

Hedge Funds Weigh In On Neuronetics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Presidio Capital Management LLC acquired a new position in Neuronetics during the 3rd quarter valued at $32,000. Intrua Financial LLC bought a new position in shares of Neuronetics during the 3rd quarter worth about $33,000. Sherbrooke Park Advisers LLC bought a new position in shares of Neuronetics during the 3rd quarter worth about $33,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Neuronetics during the second quarter valued at about $34,000. Finally, Raymond James Financial Inc. acquired a new position in shares of Neuronetics during the second quarter valued at about $37,000. Institutional investors own 53.59% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on STIM. Canaccord Genuity Group decreased their price target on shares of Neuronetics from $7.00 to $3.00 and set a “buy” rating for the company in a report on Thursday, March 19th. Wall Street Zen lowered Neuronetics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Neuronetics in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Neuronetics currently has an average rating of “Hold” and a consensus price target of $3.00.

About Neuronetics

Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.